I dentification of MHC class I-and MHC class II-binding epitopes have expedited the use of peptides in immunotherapy. Peptide vaccine strategies target T cells with fine specificity and, in combination with the appropriate adjuvants, generate immune responses to pathogens and cancers. Peptides in combination therapies may be key in the next generation of vaccines.
Many studies have used insect cells infected with baculoviruses (BV) 3 for production of proteins used in vaccines (1) (2) (3) . Due to the large viral genome and strong promoters, BV vectors accommodate large gene inserts (Ͼ1 kb) and produce high yields of mammalian proteins (4) . Furthermore, posttranslational modifications, such as glycosylation and phosphorylation, in insect cells are similar to mammalian processes, allowing expression of proteins that biochemically resemble those of mammalian origins (5) . For example, Spodoptera frugiperda (Sf9) and High Five insect cells infected with rBV produce soluble immunogenic viral proteins and viral-like particles from HIV and foot and mouth disease virus for use in vaccines (6, 7) . Both serological (8) and cellular responses (2) are elicited by purified HIV proteins produced by BV-infected insect cells, which protect animals against subsequent viral challenge. Although vaccination with protein produced by BV-infected insect cells induces Ag-specific immune responses, this vaccination strategy requires protein purification and appropriate adjuvants.
Because the BV polyhedron promoter is not active (9 -11) and BV cannot replicate in mammalian cells (12) , injection of rBV may provide effective and safe means for delivery of vaccines. rBV expressing immunogenic proteins linked to the transmembrane domain of gp64 for viral surface expression elicit Ag-specific responses (13) (14) (15) . However, rBV are inactivated by complement proteins in vivo (16) and may be damaged during purification processes, particularly by ultracentrifugation (17) .
Injection of insect cells infected with rBV is an attractive method for vaccine delivery because it combines benefits from both the protein and viral vaccines. It has been shown that these vaccines elicit humoral immune responses to surface-expressed viral Ags (18) . For example, vaccination with infected insect cells expressing foot and mouth disease virus Ag elicits seroneutralizing Abs, resulting in protection from viral challenge (7) . The recombinant proteins are produced in culture, where complement proteins do not interfere with Ag production. In addition, the Ag can be quantified before injection, and preparation of infected insect cells for vaccination requires only low-speed centrifugation. Thus, we hypothesized that vaccination with insect cells infected with BV-encoding tumor-specific Ags would be a promising technique for priming specific CD8 ϩ T cell responses. Peptide-MHC complexes and peptide-MHC libraries used for the discovery of novel peptide Ags are successfully produced by insect cells infected with rBV (19 -23) . These peptide libraries are screened for binding to soluble TCR and activation of T cells in vitro before testing the peptides in vivo. Peptides produced in the BV peptide-MHC library are soluble and not easily oxidized, which permits screening of all amino acid residues, including cysteine and tryptophan. In theory, peptide epitopes or peptide mimotopes identified using this library system may regulate the T cell response and thus the disease progression in autoimmunity, cancer, and infectious diseases (reviewed in Ref. 24) .
We are using BV peptide-MHC libraries to identify novel cancer mimotopes, or mimics of tumor peptides, which stabilize the peptide-MHC/TCR complex and elicit T cells that cross-react with the tumor Ag (23) . Like the peptide mimotopes we have identified (27) , most mimotopes used in clinical trials of cancer vaccines have alterations in the MHC-anchor residues (reviewed in Ref. 25) . We are characterizing mimotopes that improve antitumor immunity to the CT26 mouse colon carcinoma, specifically to the immunodominant tumor Ag AH1 (gp70 [423] [424] [425] [426] [427] [428] [429] [430] [431] ) (26) , restricted by the MHC class I molecule H-2L d . We previously showed that antitumor activity is improved by vaccinating with mimotope-liposome complexes (27) or mimotope-loaded dendritic cells (DCs) (28) . Because some mimotopes are insoluble in water, sensitive to oxidation, and cannot be characterized using these methods, we developed a vaccine using infected insect cells expressing peptide-MHC molecules.
We demonstrate in this study that vaccination with insect cells infected with rBV-encoding peptide-MHC complexes generates peptide-specific cytotoxic T cell responses, and, when the appropriate peptide is used, protects mice from subsequent tumor challenge. Our results indicate that the infected insect cells activate APCs in vivo, which effectively present the expressed peptides to T cells. This vaccination strategy is advantageous for the following reasons: it ensures the bone fide peptide is presented, it does not require adjuvants in addition to those produced by BV and insect cells, it greatly reduces the cost of in vivo studies by eliminating the need to synthetically generate peptides, and it expedites the direct evaluation of peptides identified in BV peptide-MHC libraries.
Materials and Methods

Cells
Sf9 and High Five insect cells (22) (Invitrogen Life Technologies) and CT26 tumor cells (29) were cultured, as described. Splenocytes from vaccinated mice were expanded in vitro with AH1 peptide and IL-2, as described (27) . DCs were prepared from collagenase-digested spleens or mesenteric lymph nodes for flow cytometric analyses or in vitro proliferation assays, as described (200 g/ml collagenase D (Roche) and 40 g/ml DNase-I (Sigma-Aldrich)) (30) . Mesenteric lymph node cells were harvested 0 (unvaccinated), 2, 8, 16, 24 , or 48 h after vaccination with infected insect cells for flow cytometric analyses. CD11c ϩ cells were isolated for in vitro proliferation assays 24 h after vaccination using a biotinylated CD11c-specific mAb and anti-biotin microbeads. Labeled cells were separated using LS MidiMacs columns, according to the manufacturer's protocol (Miltenyi Biotec).
Mice
CT26-specific TCR transgenic (CT-TCR Tg) mice expressing the TCR from the V␤8.3/V␣4.11 T cell clone (28) were generated by inserting the TCR ␣ and ␤ genes into shuttle vectors (31) , which were subsequently injected into embryos of (SJL ϫ B6)F 1 at the University of Pennsylvania Transgenic Facility, and backcrossed to BALB/c 12 generations. Because of low TCR expression, these mice were bred onto a RAG2-deficient background (C.12956(B6)-RAG2 tm1fwa N12; Taconic Farms). Six-to eight-wkold female BALB/c were purchased from the National Cancer Institute/ Charles River Laboratories. All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee of National Jewish Medical and Research Center.
Proteins
Sequence encoding H-2L d with either a peptide tag for biotinylation by the enzyme BirA (L d BirA (27) ) or the transmembrane domain from gp64 (L d TM (22, 32) ) was inserted into a modified pBacp10pH BV expression vector downstream of the p10 promoter (20) . Sequence encoding mouse ␤ 2 -microglobulin (␤ 2 m) with covalently linked peptides (AH1, SPSYVY HQF (26); 39, MNKYAYHML (27); 15, MPKYAYHML (27) ; ␤-galactosidase (␤-gal), TPHGAGRIL (33); WMF, SPTYAYWMF (23)) was inserted downstream of the pH promoter. The constructions were introduced into BV using the standard homologous recombination method (22) . AH1 peptide-loaded L d BirA used for the ELISA standard was purified from supernatants of infected High Five insect cells over an affinity column using an Ab specific for H-2L d (28.14.8s; American Type Culture Collection). Protein-containing fractions were concentrated and separated on a Superdex-200 sizing column. AH1 peptide (Macromolecular Resources) was added to the 57-kDa fraction in 5-fold molar excess. Fluorescent tetramer was prepared, as described (27) .
Abs and staining reagents
Soluble TCR was constructed by inserting the TCR-encoding V region gene fragments from CT-Ig (28) into a modified pBacp10pH BV expression vector (23) . CT-TCR-soluble protein was purified from supernatants of infected High Five insect cells over an affinity column using an Ab specific for TCR C␤ (HAM-597; American Type Culture Collection) and a Superdex-200 sizing column. Purified CT-TCR was multimerized with a biotinylated anti-TCR C␣-specific Ab (ADO-304) and streptavidin-AF647 (Invitrogen Life Technologies), as previously described (22 
Infection of Sf9 insect cells
A total of 3 ϫ 10 7 Sf9 insect cells was cultured in T175 flasks in complete Grace's Insect medium (Invitrogen Life Technologies) containing 10% FCS (Atlanta Biologicals), 1% F-68 detergent (Invitrogen Life Technologies), and 1% antibiotic-antimycotic (Invitrogen Life Technologies). The BV titer was determined using a limiting dilution assay. When a multiplicity of infection of 2 U/cell is used for each infection, consistent infection efficiencies and insect cell death rates (20% by day 3) are obtained. Infected Sf9 insect cells were incubated for 3 days, harvested by centrifugation at 1000 ϫ g for 5 min, and washed three times with HBSS (Mediatech).
Vaccination
Infected Sf9 insect cells were resuspended in HBSS, and 5 ϫ 10 6 cells were injected i.p. on days 0 and 7. The number of responding Ag-specific T cells is similar following i.v. and s.c. injection. Splenocytes or PBMCs were harvested for flow cytometric analyses on days 10, 14, and 17. Statistical analyses were performed with Prism version 4.0 (GraphPad), using unpaired two-tailed Student's t test. A p value of Ͻ0.05 was considered statistically significant.
Immunoprecipitation of H-2L d from whole cell lysates
Whole cell lysates were prepared by incubating infected Sf9 insect cells in lysis buffer and protease inhibitors, as previously described (34), at a concentration of 1 ϫ 10 7 cells/ml for 4 h at 4°C. H-2L d was immunoprecipitated from whole cell lysates with the 28.14.8s Ab and protein A-Sepharose beads (35) . Precipitated proteins were separated by SDS-PAGE (5-20% Tris-HCl; Bio-Rad) under reducing conditions using a standard protocol and stained with Coomassie blue.
In vivo killing assays
Mice were vaccinated with 39-L d TM-infected or uninfected insect cells on days 0 and 7. Thirty days after the last vaccination, target cells (BALB/c splenocytes) were incubated with either ␤-gal or AH1 peptide (10 g/ml) for 2 h at room temperature. Cells were washed and labeled with 0.2 M or 2 M CFSE, respectively, and injected i.v. Splenocytes were harvested 20 h later, and the number of CFSE ϩ cells in each peak was determined (percentage of specific killing ϭ 1 -percentage of survival; percentage of survival ϭ (number of AH1 targets remaining)/(number of ␤-gal targets remaining)). Groups were compared using Prism version 4.0 (GraphPad), by unpaired two-tailed Student's t test. A p value of Ͻ0.05 was considered statistically significant.
Proliferation assays
For in vivo proliferation assays, mice were vaccinated, as described above, with either 39-L d TM-infected or uninfected insect cells on day Ϫ7, Ϫ3, or Ϫ1. A total of 1 ϫ 10 7 splenocytes from CT-TCR Tg mice was labeled with 10 M CFSE and transferred into vaccinated mice on day 0. Three days later, CFSE dilution of transferred V␤8.3 ϩ CD8 ϩ splenocytes was determined by flow cytometry. Background proliferation was determined in mice vaccinated with uninfected insect cells.
For in vitro proliferation assays, 5 ϫ 10 5 CFSE-labeled splenocytes (labeled as above) from CT-TCR Tg mice were incubated in 96-well plates at 37°C with increasing concentrations of soluble peptide or 1 ϫ 10 5
CD11c
ϩ splenocytes preincubated with 100 g/ml peptide or from vaccinated mice in complete medium (27) . Cells were harvested 3 days later, and CFSE dilution of 7-aminoactinomycin D Ϫ CD8 ϩ cells was analyzed by flow cytometry. In vitro proliferation assays using a T cell clone expressing the CT-TCR were performed, as previously described (27) . The T cell clone was incubated at a 5:1 ratio with insect cells that express ICAM and B7 costimulatory molecules (22) and infected with BV-encoding peptide-MHC. (26) . Tumor-free survival was assessed by palpation of the injection site. Once tumors were palpable, they always proceeded to 100 mm 2 without shrinking. When a tumor reached 100 mm 2 , the mouse was no longer considered tumor free, as indicated on the Kaplin-Meier plot, and it was sacrificed. All mice are represented in the Kaplin-Meier plot. Tumor-free survival was analyzed by Kaplan-Meier survival plots, and statistical significance was analyzed with Prism version 4.0 (GraphPad), using the log rank test.
Tumor challenge
For tumor treatment experiments, mice were injected with 5 ϫ 10 4 CT26 tumor cells and vaccinated with 5 ϫ 10 6 infected insect cells 2, 5, 8, 11, and 14 days later. Tumors were measured every 2 days, and groups were compared statistically on individual days using Prism version 4.0 (GraphPad) with unpaired two-tailed Student's t test. A p value of Ͻ0.05 was considered statistically significant. Differences in tumor size of mice injected with 39-L d TM relative to unvaccinated or ␤-gal-L d TM were statistically significant after day 9. The average tumor size of the indicated number of mice is plotted.
Results
BV-infected insect cells express peptide-L d TM
To ensure that insect cells infected with BV produce Ag recognized by cognate TCR, we generated BV-encoding peptide-L d molecules. The transmembrane domain of BV gp64 was inserted downstream of H-2L d for surface expression (L d TM) (6, (21) (22) (23) , and peptides were tethered to the ␤ 2 m molecule via a glycine-rich linker. We inserted either the CT26 tumor Ag (the AH1 peptide) or the negative control ␤-gal peptide, which binds to H-2L d , but is not recognized by the AH1-specific TCR (CT-TCR). To ensure that the cognate TCR recognizes peptides produced in insect cells with similar relative affinity as synthetic peptides, we also generated BV-encoding H-2L d covalently linked to previously studied peptide mimotopes with changes in the MHC-binding residues of different affinities (27) . The CT-TCR binds to mimotope 39-L d with an intermediate affinity and to mimotope 15-L d with a high affinity, referring to the peptide-MHC/TCR interaction, as determined by surface plasmon resonance (27) .
Three days after infection with BV, insect cells were stained with Abs specific for H-2L d bound to ␤ 2 m and peptide (28.14.8s) and soluble TCR multimer (predicted octamer, CT-TCR) (23) . As shown previously, the amount of MHC expression on the surface of the insect cells correlates with the extent of viral infection (22) and is consistent between experiments. Thus, TCR staining within a given intensity of MHC staining, represented by the thin gate in Fig. 1a , can be compared between samples because the insect cells are infected similarly.
As expected, similar amounts of H-2L d protein were detected on the surface of insect cells infected with BV encoding all of the peptide-
was detected with the H-2L
d Ab, but not with the CT-TCR, demonstrating specificity of the CT-TCR reagent (Fig. 1a) . Importantly, as shown with other BV-encoded peptide-MHC complexes (22) , the CT-TCR fluorescence intensity directly correlated with its affinity for the peptide-MHC molecules (Fig. 1b) (22) , as follows: binding affinity of the peptide-MHC/TCR interaction can be readily analyzed using these BV constructions.
BV-infected insect cells stimulate peptide-specific immune responses in vivo
We hypothesized that the infected insect cells provide both an Ag-specific signal and adjuvant from the combination of BV and foreign insect cells. To determine whether infected insect cells induce antitumor responses in vivo, we analyzed AH1-specific CD8 ϩ T cells following injection of these cells. To produce this vaccine, we infected Sf9 insect cells for 3 days, harvested and washed the cells, then injected them i.p. Although the insect cells were washed, remaining free virus and dead insect cells were also included.
We previously showed that vaccination with the intermediate affinity mimotope 39 in liposomes elicits tumor-specific T cells and protects ϳ50% of mice from tumor growth (27) . Although the high-affinity mimotope 15 elicits tumor-specific T cells, it does not protect mice from tumor growth. Thus, for simplicity we used insect cells infected with 39-L d TM throughout the following experiments. As shown in Fig. 2a, AH1 -specific (tumor-specific), but not ␤-gal-specific, T cells were elicited after injection of insect (Fig. 2a) . This increase was most evident 7 days after the second injection (day 14), as determined by the average frequency of tetramer-positive PBMCs on days 10, 14, and 17 ( Fig. 2b) . Although there are stochastic differences in the frequency of AH1-L d tet ϩ T cells, the increase in the percentage of these T cells at day 14 is significantly different from day 17. Significant expansion of AH1-L d tet ϩ T cells was not detectable before the second injection (data not shown). There was minimal background ␤-gal-tetramer staining in these experiments (Յ0.2%, Fig. 2a) , and no adverse side effects were observed in the injected mice.
To determine the amount of Ag delivered by this vaccine, we compared the amount of H-2L d protein in the infected insect cell vaccine to a standard curve of purified H-2L d by ELISA using conformation-specific Abs. The vaccine was prepared for the ELISA as it was for injection. We calculated that insect cells infected with 39 We next determined whether vaccine-elicited T cells were functional in an in vivo killing assay (Fig. 2, c and d) . Splenocytes from BALB/c mice were incubated with AH1 or ␤-gal peptides and labeled with a high or low concentration of CFSE, respectively. These labeled splenocytes were transferred into vaccinated BALB/c mice 30 days following the second injection of 39-L d TMinfected insect cells. AH1 peptide-loaded target cells were specifically eliminated in mice vaccinated with 39-L d TM-infected insect cells, but not with uninfected insect cells (Fig. 2d) . The number of ␤-gal-loaded targets remained similar in both samples. These results indicate that 39-L d TM-infected insect cells elicit effector T cells that specifically kill Ag-loaded target cells in vivo. Thus, the same viral constructions can be used for in vivo and in vitro analyses.
Persistence of peptide-L d TM Ag in vivo
To analyze T cell responses to this vaccine and ultimately to design mimotopes to tumor-associated Ags, we derived Tg mice that express the TCR from the CT-T cell clone (28), a clone that recognizes the AH1 peptide restricted by H-2L d . Like many other T cells that recognize tumors, this T cell clone recognizes a self Ag, and therefore is subject to negative selection in the thymus and peripheral tolerance after leaving the thymus. We developed this new Tg mouse model, rather than using an established Tg strain, such as the OT-1 mice, to better mimic T cell tolerance encountered by tumor vaccines. We backcrossed the transgenes onto BALB/c mice for 12 generations and then crossed the transgenes onto RAG2-deficient mice. Approximately 90% of the T cells in the thymus of these Tg mice are coreceptor negative (data not shown), indicating the following: 1) strong negative selection of the T cells during development; 2) a developmental block in the T cells at the double-negative stage, because the CT-TCR is specific for a self peptide derived from an endogenous retroviral gene product, gp70; and/or 3) the Ig enhancer used to drive gene expression is suboptimal (31). As in other models of self tolerance, some T cells escape negative selection and are found in the periphery (37) . Some of the peripheral V␤8.3 ϩ T cells from the Tg mice express CD8 molecules, and these T cells are functional, as determined by tetramer binding and other assays (Fig. 3) . The coreceptor-negative cells bind a V␤8.3 Ab (Fig. 3b ), but they do not all bind to AH1-L d tet (Fig. 3a) , suggesting that T cells lacking coreceptor may require a higher affinity peptide to form a complex. Consistent with this possibility, more coreceptor-negative T cells bind 39-L d tet than AH1-L d tet (data not shown). Eighty to 90% of the CD8 ϩ T cells proliferated when incubated with 10 nM peptide 39 (Fig. 3d) . Few of the T cells express CD4 molecules, and the remaining T cells are coreceptor negative (CD4 Ϫ /CD8 Ϫ , Fig. 3b ). The CT-TCR Tg RAG mouse produced functional Ag-specific T cells, as determined by production of IFN-␥ and proliferation to a range of peptide concentrations (Fig. 3, c and d) . Thus, we determined that these T cells may be used to monitor Ag-specific T cell responses in adoptive transfer assays and other assays to assess tumor-specific T cell responses.
Ag persistence, or t 1/2 , directly correlates to the potency of a vaccine (38) . To determine the persistence of Ag following injection of the BV-infected insect cell vaccine, we analyzed proliferation of transferred splenocytes from CT-TCR Tg RAG mice. BALB/c mice were vaccinated with 39-L d TM-infected or uninfected insect cells, and 1 ϫ 10 7 CFSE-labeled Tg splenocytes were transferred i.v. 1, 3, or 7 days after vaccination. Splenocytes were harvested 72 h after transfer, and proliferation of CD8 ϩ /V␤8.3 ϩ /CFSE ϩ cells was determined by flow cytometric analysis (Fig. 3e) . Vaccination with 39-L d TM-infected insect cells 1 day before transfer induced proliferation of a significant number of Tg T cells (37%). Proliferation in mice vaccinated 3 days before transfer was reduced (16%), although it was significantly higher than in mice vaccinated with uninfected insect cells. Vaccination 7 days before transfer did not induce proliferation of Tg T cells, indicating that most of the Ag is cleared between 3 and 7 days after vaccination. The persistence of infected insect cells is similar to vaccination with Ag and IFA, which are cleared 6 -8 days following injection (39) .
Infected insect cells do not directly stimulate T cells in vivo
Although rBV that express both peptides and MHC molecules is convenient and effective for both in vitro and in vivo analyses, we wanted to determine whether Ag is presented directly by insect cells, cross-presented by APCs, or presented using a novel mechanism. To determine whether insect cells directly (Fig. 4a) and ELISA (data not shown) of whole insect cell lysates 3 days after infection. Although 39-␤ 2 m molecules may be detectable in whole cell lysates (Fig. 4a) , they are not detectable by immunoprecipitation or ELISA because these assays are specific for H-2L (Fig. 4c) . In addition, surface expression on insect cells infected with 39-L d TM that also express costimulatory molecules ICAM-1 and B7.1, facilitators of direct Ag presentation and T cell priming, did not increase the number of responding AH1-specific T cells (data not shown). These results suggest that infected insect cells do not present Ag directly to T cells, but are processed by APCs, which present the peptides in the context of H-2L d to CD8 ϩ T cells.
Vaccination with infected insect cells induces maturation of DC subsets
To determine whether the insect cell vaccine activates APCs as expected, we examined surface markers on DCs after vaccination. Mice were vaccinated with 39-L d TM-infected insect cells, and DCs from the draining mesenteric lymph nodes were characterized over time. DCs were stained with Abs against the DC subset markers CD11c, CD8, and CD11b, and the maturation markers MHC class II, CD80, CD86, and CD70. We observed an increase in the expression of MHC class II and the costimulatory molecules CD80 and CD86 in both DC populations (Fig.  5a) . Expression of CD70, a molecule expressed by activated DCs that was recently shown to be necessary for optimal T cell stimulation (40) , also increased (Fig. 5a) . Similar results were obtained for DC populations in the spleen (data not shown). Although the vaccine stimulated both CD8 ϩ CD11c ϩ and CD11b ϩ CD11c ϩ cells, up-regulation of the costimulatory molecules CD80 and CD86 was more pronounced in the CD8 ϩ
CD11c
ϩ subset, suggesting that these cells respond more vigorously to the vaccine. The infected insect cell vaccine induces maturation of DCs, particularly the CD11c ϩ CD8 ϩ DCs, consistent with a function in cross-presentation (41).
DCs cross-present insect cell-derived peptides
To confirm that Ags from infected insect cell vaccines can be cross-presented by DCs, we determined whether DCs isolated from mice vaccinated with 39 (Fig. 5b, black lines) . Tg T cells did not proliferate when incubated with DCs exogenously loaded with ␤-gal peptide or DCs from mice vaccinated with uninfected insect cells (Fig. 5b, dashed lines) . These results indicate that peptides from infected insect cells may be cross-presented by DCs in the spleen within 24 h of vaccination.
BV-infected insect cells induce protective antitumor immunity
We previously showed that vaccination with peptide 39 protects mice from tumor challenge (27) . To ensure that vaccination with peptides produced in insect cells elicits similar antitumor responses as synthetic peptides, we tested the vaccine in tumor protection and therapeutic assays. Mice were vaccinated with 39- (Fig. 6a) .
We next determined the therapeutic efficacy of vaccination with infected insect cells. We injected mice with 5 ϫ 10 4 tumor cells and vaccinated 2, 4, 7, 10, and 14 days later with 39- (Fig. 6b ). We observed a statistically significant delay in tumor growth in mice injected with 39-L d TM-infected insect cells, although no mice remained tumor free. These results show that Ag-specific T cells, elicited by the infected insect cell vaccine, slowed the growth of the tumor, but did not eliminate it.
In vivo assessment of a water-insoluble mimotope with high affinity in the peptide-MHC/TCR interaction identified in a BV peptide library
Finally, we determined whether peptides identified in the BV peptide library could be analyzed in vivo using this method. The synthetic peptide designated WMF (SPTYAYWMF) (23), a mimotope of the AH1 Ag, was identified in a BV peptide library with substitutions in the MHC-contact residues. This peptide is insoluble in water and is difficult to synthesize, indicated by the heterogeneity of HPLC and mass spectrometry profiles (data not shown). However, the WMF peptide produced in infected insect cells binds to CT-TCR with high affinity relative to peptide 39 ( Fig. 7a) and stimulates a corresponding amount of proliferation of the CT-T cell clone (Fig. 7b ). These experiments demonstrate that the WMF peptide-H-2L d complex is produced in insect cells and specifically binds to both soluble CT-TCR molecules and T cells expressing CT-TCR. (Fig. 7c) . Although the affinity of the WMF peptide in the peptide-MHC/TCR interaction is higher than the intermediate-affinity 39 peptide, fewer AH1-specific T cells were detected in the blood after vaccination with WMF-L d TM-infected insect cells. In addition, vaccination with 39-L d TM-infected insect cells protected the majority of mice from subsequent CT26 tumor challenge, whereas vaccination with (Fig. 7d) . These results are consistent with those in Fig. 6 and our previous results showing that peptides that form an intermediate-affinity peptide-MHC/TCR complex with substitutions in the MHC-contact residues, such as the 39 peptide, protect mice from tumor challenge (27) , whereas those that form a low (AH1)-or high (peptide 15 or WMF)-affinity peptide-MHC/TCR complex do not.
Discussion
We have shown that vaccination with BV-infected insect cells expressing peptide-MHC complexes generates functional Ag-specific CD8 ϩ T cell responses. This vaccine, which protects against tumor challenge and delays growth of tumors, is convenient in that it does not require additional adjuvants to those provided by the BV and insect cells; it eliminates the need, expense, and potential artifacts of synthesizing peptides identified in the BV peptide library before evaluation; and it does not require purification of proteins or BV before injection. Vaccination with infected insect cells expressing other recombinant proteins also results in specific immune cell responses. For example, we have used this vaccination strategy to develop TCR-specific Abs (data not shown). Like with the peptide-MHC vaccine, vaccination with infected insect cells expressing recombinant proteins eliminates the need for protein purification.
This vaccine strategy is unique and cannot be practically achieved using other strategies because it provides a method to analyze peptides identified in BV peptide-MHC libraries that are otherwise technically difficult to evaluate, such as the WMF peptide (Fig. 7) . Amino acids such as cysteine, methionine, and tryptophan are often avoided in peptide libraries due to disulfide bonding, insolubility, and sensitivity to oxidation (27, 42) . Small molecular changes in amino acid residues of the peptide, such as oxidation or alkyl-chain modifications, can alter epitopes and thus elicit different T cell responses (43, 44) . Furthermore, vaccination with synthetic peptides does not always stimulate T cells that recognize endogenously processed peptides, possibly due to oxidation or cysteinylation of amino acid residues during peptide synthesis or handling (45) (46) (47) . Although oxidation does not affect the T cell response to all Ags, in the BV-infected insect cell vaccine strategy, the peptide is produced, processed, and cross-presented in a reduced intracellular environment similar to natural tumor Ags.
In vitro characterization of peptides derived from libraries requires coexpression of MHC molecules and peptides. Insect cells infected with rBV-encoding peptide, H-2L d , and ␤ 2 m molecules bind H-2L d -specific Abs and the AH1-specific CT-TCR, suggesting that the protein structure is similar to that of mammalian cells. Furthermore, the avidity of the peptide-MHC/TCR complexes correlates with the affinity of the soluble mimotope-MHC/TCR complexes ( Fig. 1) (27) . In addition to binding assays for characterization of peptides, other in vitro studies using infected insect cells examine T cell function, such as cytokine production (21, 22) . In vivo, insect cells expressing peptide 39 restricted by H-2L
d elicit a population of T cells that binds Ag-loaded tetramer (Fig. 2, a and  b) , kills Ag-loaded target cells (Fig. 2, c and d) , and protects 67% of mice from subsequent tumor challenge (Fig. 6a) . These proofof-concept experiments indicate that the T cells elicited by infected insect cells recognize native peptide on tumor cells. To analyze the mechanism of priming by this vaccine, we developed a new Tg mouse that expresses the ␣-and ␤-chains of a TCR specific for the AH1/H-2L d Ag. This TCR was derived from a BALB/c mouse vaccinated with irradiated CT26 tumor cells expressing GM-CSF (28), i.e., a T cell clone that had escaped negative selection in the thymus. Because T cells from this mouse recognize a tumor/self Ag, we are including them in our analyses to determine the requirements of peptide vaccines that break tolerance. Not all tumor-specific T cells generated in this mouse express CD8 molecules, suggesting that down-regulation of the CD8 molecule is a consequence of tolerance, as reported by others (48, 49) . Alternatively, aberrant expression of the TCR during T cell development may disrupt the expression of the CD8 molecule. The Ag-specific response of the CD3 ϩ CD8 Ϫ T cells is less robust relative to the CD3 ϩ CD8 ϩ cells, suggesting that the coreceptor contributes to the binding avidity of the TCR complex. Consistent with this possibility, more coreceptor-negative T cells bind 39-L (Fig. 4a) . 2) When the vaccine encodes peptide, but no MHC molecules (peptide-␤ 2 m), similar responses are elicited (Fig. 4) . In this experiment, the only MHC available to present peptide is from the host cells, not the vaccine. 3) This vaccine induces maturation of CD11c ϩ DCs from the draining lymph nodes (mesenteric) and spleen as determined by increased expression of costimulatory and maturation markers CD80, CD86, MHCII, and CD70 (Fig. 5a ). The expression of CD70, a maturation marker whose expression correlates with optimal expansion of CD8 ϩ T cells following vaccination with both CD40 ligands and TLR agonists (51), increased on DCs after vaccination. 4) CD11c ϩ cells from vaccinated mice stimulate Tg T cells to proliferate in an Ag-specific manner ex vivo. No additional Ag or adjuvant is added in these experiments (Fig. 5b) . 5) When the vaccine expresses costimulatory molecules (ICAM and B7), the T cell response to the vaccine is unchanged (data not shown). 6) Finally, it is unlikely that peptide-MHC molecules are produced in BV-infected DCs because the polyhedron promoter driving transcription of the Ags is active only in insect cells (9 -11) . This feature of BV makes them safe to work with. Alternatively, extracellular Ag processing and presentation by DCs stimulate CD4 ϩ T cells (52) . A similar mechanism in which MHC I-restricted peptides are loaded onto DCs is possible. However, because this vaccine delivers only an estimated 200 ng of peptide and 10 g of free peptide is required for similar responses (27) , this mechanism most likely accounts for a small fraction of the T cell response. Thus, like other vaccine delivery systems (53), the injected insect cells do not present Ags directly, but activate T cells by transferring the Ag to host professional APCs, resulting in effective priming of tumor-specific T cell responses. In summary, use of these BV peptide-MHC constructions provides a streamlined system for evaluation of newly discovered peptides.
